ANGLE PLC's (LON:AGL) Andrew Newland talks to Proactive London's Katie Pilbeam about securing their first large-scale pharma services contract for their cancer cell collection system Parsortix.
Newland says 'it's a great day for Angle shareholders' after announcing the contract, worth up to US$1.2mln over 18 months and covers work on a large Phase III prostate cancer study and two smaller Phase I studies.
